Your browser doesn't support javascript.
loading
Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.
Zignol, Matteo; Dean, Anna S; Alikhanova, Natavan; Andres, Sönke; Cabibbe, Andrea Maurizio; Cirillo, Daniela Maria; Dadu, Andrei; Dreyer, Andries; Driesen, Michèle; Gilpin, Christopher; Hasan, Rumina; Hasan, Zahra; Hoffner, Sven; Husain, Ashaque; Hussain, Alamdar; Ismail, Nazir; Kamal, Mostofa; Mansjö, Mikael; Mvusi, Lindiwe; Niemann, Stefan; Omar, Shaheed V; Qadeer, Ejaz; Rigouts, Leen; Ruesch-Gerdes, Sabine; Schito, Marco; Seyfaddinova, Mehriban; Skrahina, Alena; Tahseen, Sabira; Wells, William A; Mukadi, Ya Diul; Kimerling, Michael; Floyd, Katherine; Weyer, Karin; Raviglione, Mario C.
Afiliação
  • Zignol M; Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland. Electronic address: zignolm@who.int.
  • Dean AS; Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
  • Alikhanova N; Scientific Research Institute of Lung Diseases, Baku, Azerbaijan.
  • Andres S; National and Supranational Reference Laboratory for Mycobacterium, Borstel, Germany.
  • Cabibbe AM; IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Cirillo DM; IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Dadu A; Regional Office for Europe, World Health Organization, Copenhagen, Denmark.
  • Dreyer A; National Institute for Communicable Diseases, Sandringham, South Africa.
  • Driesen M; Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium.
  • Gilpin C; Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
  • Hasan R; Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan.
  • Hasan Z; Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan.
  • Hoffner S; Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
  • Husain A; National Tuberculosis Control Programme, Dhaka, Bangladesh.
  • Hussain A; National Tuberculosis Reference Laboratory, National Tuberculosis Control Programme, Islamabad, Pakistan.
  • Ismail N; National Institute for Communicable Diseases, Sandringham, South Africa; University of Pretoria, Pretoria, South Africa.
  • Kamal M; National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh.
  • Mansjö M; Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden.
  • Mvusi L; Tuberculosis Control and Management, National Department of Health, Pretoria, South Africa.
  • Niemann S; National and Supranational Reference Laboratory for Mycobacterium, Borstel, Germany.
  • Omar SV; National Institute for Communicable Diseases, Sandringham, South Africa.
  • Qadeer E; National Tuberculosis Control Programme, Ministry of National Health Services, Regulation and Coordination, Islamabad, Pakistan.
  • Rigouts L; Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium; Biomedical Sciences, Antwerp University, Antwerp, Belgium.
  • Ruesch-Gerdes S; National and Supranational Reference Laboratory for Mycobacterium, Borstel, Germany.
  • Schito M; Critical Path Institute, Tucson, AZ, USA.
  • Seyfaddinova M; Scientific Research Institute of Lung Diseases, Baku, Azerbaijan.
  • Skrahina A; Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus.
  • Tahseen S; National Tuberculosis Reference Laboratory, National Tuberculosis Control Programme, Islamabad, Pakistan.
  • Wells WA; Bureau for Global Health, US Agency for International Development, Washington, DC, USA.
  • Mukadi YD; Bureau for Global Health, US Agency for International Development, Washington, DC, USA.
  • Kimerling M; KNCV Tuberculosis Foundation, The Hague, Netherlands.
  • Floyd K; Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
  • Weyer K; Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
  • Raviglione MC; Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
Lancet Infect Dis ; 16(10): 1185-1192, 2016 10.
Article em En | MEDLINE | ID: mdl-27397590
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazinamida / Vigilância da População / Tuberculose Resistente a Múltiplos Medicamentos / Fluoroquinolonas / Anti-Infecciosos / Mycobacterium tuberculosis / Antituberculosos Tipo de estudo: Observational_studies / Risk_factors_studies / Screening_studies Limite: Humans País/Região como assunto: Africa / Asia Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazinamida / Vigilância da População / Tuberculose Resistente a Múltiplos Medicamentos / Fluoroquinolonas / Anti-Infecciosos / Mycobacterium tuberculosis / Antituberculosos Tipo de estudo: Observational_studies / Risk_factors_studies / Screening_studies Limite: Humans País/Região como assunto: Africa / Asia Idioma: En Ano de publicação: 2016 Tipo de documento: Article